Protocol - Quality of Life in Cancer Survivors - Active Treatment
Description
Self-reported 30-item Likert style questions assessing quality of life and health, during the past week, in cancer patients during active treatment.
Specific Instructions
None
Availability
Protocol
The European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Core 30 (QLQ-C30) © was developed to assess the quality of life in cancer patients. It is a copyrighted instrument, which has been translated and validated in over 110 languages and has been used in more than 3,000 studies worldwide. Presently QLQ-C30 Version 3.0 © is the most recent version and should be used for all new studies.
The instrument is freely available if your study is purely for academic use. For each study, researchers are required to have an Academic User Agreement in order to use EORTC protocols.
Studies with commercial sponsorship are required to have a Commercial User Agreement in order to use this protocol, and a fee is requested dependent on the number of patients in the study.
In order obtain the QLQ-C30 and associated modules, obtain the permission via the download process on the EORTC website https://qol.eortc.org/questionnaires/.
Personnel and Training Required
None
Equipment Needs
None
Requirements
| Requirement Category | Required |
|---|---|
| Major equipment | No |
| Specialized training | No |
| Specialized requirements for biospecimen collection | No |
| Average time of greater than 15 minutes in an unaffected individual | No |
Mode of Administration
Self-administered questionnaire
Lifestage
Adult, Senior
Participants
Ages 18 and older
Selection Rationale
This questionnaire was developed to assess the quality of life of cancer patients. It has been translated and validated into over 110 languages and was used in more than 3,000 studies worldwide.
Language
English
Standards
| Standard | Name | ID | Source |
|---|
Derived Variables
None
Process and Review
Not Applicable
Protocol Name from Source
Quality of Life in Cancer Patients European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30)
Source
European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Core 30 (QLQ-C30)
General References
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., & de Haes, J. C. (1993). The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376. https://doi.org/10.1093/jnci/85.5.365
Nolte S1, Liegl G2, Petersen MA3, Aaronson NK4, Costantini A5, Fayers PM6, Groenvold M7, Holzner B8, Johnson CD9, Kemmler G8, Tomaszewski KA10, Waldmann A11, Young TE12, Rose M13; EORTC Quality of Life Group. General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States. Eur J Cancer. 2019 Jan;107:153-163.
Quinten C, Coens C, Ghislain I, Zikos E, Sprangers M, Ringash J, Martinelli F, Ediebah D, Maringwa J, Reeve B, Greimel E, King M, Bjordal K, Flechtner H, Schmucker-Von Koch J, Taphoorn M, Weis J, Wildiers H, Velikova G, Bottomley A. The effects of age on health-related quality of life in cancer populations: A pooled analysis of randomized controlled trials using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 involving 6024 cancer patients. Eur J Cancer 2015; 51 (18):2808-2819.
Scott NW, Etta JA, Aaronson NK, Bottomley A, Fayers PM, Groenvold M, Koller M, Kulis D, Marais D, Petersen MA, Sprangers M. An evaluation of the response category translations of the EORTC QLQ-C30 questionnaire. Qual Life Res 2013; 22:1483-1490.
Zeng L, Chow E, Zhang L, Tseng LM, Hou M-F, Fairchild A, Vassiliou V, Jesus-Garcia R, Alm El-Din MA, Kumar A, Forges F, Chu Chie W, Bedar G, Bottomley A. An international prospective study establishing minimal clinically important differences in the EORTC QLQ-BM22 and QLQ-C30 in cancer patients with bone metastases. 2012.
Martinelli F, Quinten C, Maringwa JT, Coens C, Vercauteren J, Cleeland CS, Flechtner H, Gotay C, Greimel E, King M, Mendoza T, Osoba D, Reeve BB, Ringash J, Koch JS, Shi Q, Taphoorn MJ, Weis J, Bottomley A. Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Rev Pharmacoecon Outcomes Res 2011.
Maringwa J, Quinten C, King M, Ringash J, Osoba D, Coens C, Martinelli F, Reeve BB, Gotay C, Greimel E, Flechtner H, Cleeland CS, Schmucker-Von Koch J, Weis J, Van Den Bent MJ, Stupp R, Taphoorn MJ, Bottomley A. Minimal clinically meaningful differences for the EORTCQLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 2011.
Protocol ID
320901
Variables
Export Variables| Variable Name | Variable ID | Variable Description | dbGaP Mapping |
|---|
Measure Name
Quality of Life in Cancer Survivors
Release Date
December 17, 2020
Definition
Questionnaire assessing health-related quality of life in cancer survivors.
Purpose
Concerns about health-related quality of life are important to cancer survivors and their families, as well as caregivers and care providers.
Keywords
European Organisation for the Research and Treatment of Cancer (EORTC): Cancer Outcomes and Survivorship
Measure Protocols
| Protocol ID | Protocol Name |
|---|---|
| 320901 | Quality of Life in Cancer Survivors - Active Treatment |
| 320902 | Quality of Life in Cancer Survivors - Long-term |
Publications
There are no publications listed for this protocol.